Summary.-Lymphocyte sensitivity to encephalitogenic factor (EF) was measured with the macrophage migration inhibition (MMI) test in 60 women with dysplasia or carcinoma in situ of the cervix, in 10 women with invasive cervical carcinoma, and in 20 women with a variety of benign gynaecological conditions. Significant migration inhibition with EF (P<0-01) was seen with lymphocytes taken from 7/13 (54%) women with mild and/or moderate dysplasia, from 22/47 (47%) women with severe dysplasia and/or carcinoma in situ, from 6/10 (60%) women with invasive cervical carcinoma and from 3/20 (15%) women with benign gynaecological conditions.
SINCE the original observation by Field & Caspary (1970) that lymphocytes respond to encephalitogenic factor (EF) in the macrophage electrophoretic mobility (MEM) test, there is now evidence to suggest that this response is directed against a common neoantigen or common neoantigens on the tumour cell surface (Caspary & Field, 1971; Coates & Carnegie, 1975) . Similar results have been reported using the macrophage migration inhibition (MMI) test (Light et al., 1975) but this test may be less sensitive than the MEM test (Hughes & Paty, 1971) . Moreover, there is further evidence that the lymphocyte response to EF may occur many years before the clinical appearance of tumour Pritchard et al., 1976) . Thus Singer and co-workers (1975) and Porzsolt et al. (1975) have shown that a large proportion of women with premalignant cervical lesions and carcinoma in situ show a lymphocyte response to EF. Furthermore Flavell et al. (1978) , using an animal model, have demonstrated that about half the rats with carcinogen-induced dysplastic hepatic lesions show a spleen-cell response to EF in the MMI test. In view of this evidence, it seems possible that the demonstration of a cell-mediated immune response to EF may prove useful in detecting not only cervical premalignant lesions but premalignant lesions at other sites.
In the present paper we report on the incidence of a cell-mediated immune response to EF as determined with the MMI test in women with premalignant and malignant cervical lesions, and in a group of women with a variety of benign gynaecological conditions. In addition, the effects of autologous serum on the lympho-cyte response to EF was investigated in some of the patients.
MATERIALS AND METHODS
Patients.-A total of 60 women with either dysplasia or carcinoma in situ of the cervix were selected for study. Diagnosis was made histologically from punch-biopsy specimens taken at colposcopy, according to the criteria described by the R.C.O.G. panel (Govan et al., 1969) and by W.H.O. (Riotton and Christopherson, 1973) . Because of the difficulties often encountered in discriminating histologically between mild and moderate dysplasia or severe dysplasia and carcinoma in situ (Koss, 1978) these 2 sets of lesions were grouped together in the study. When both types of lesion were present, the more severe was accepted as representative. The group of 13 women with mild and/or moderate dysplasia had a mean age of 24 years (range 19-42) whilst the group of 47 women with severe dysplasia and/or carcinoma in situ had a mean age of 33 years (range 18-56). A group of 10 women with invasive cervical carcinoma were also included in the study; they had a mean age of 46 years (range 30-65). A group of 20 women with various benign gynaecological conditions was also included in the study. Their individual diagnoses are given in Table  I . They had a mean age of 32 years (range 16-59).
MMI test.-Lymphocytes harvested from peripheral blood (Harris and Ukaejiofo, 1970) were tested for response to EF using the direct M:MI test. Full details of this test system have been given elsewhere (Flavell and Potter, 1978) . Briefly, lymphocytes and peritoneal-exudate cells from guinea-pigs stimulated with i.p. liquid paraffin (Rees and Potter, 1973) were mixed in a ratio of 1:5 and packed into lOuil capillary tubes. Cut capillary tubes were incubated in Medium 199 containing 10% heat-inactivated foetal calf serum in the absence or in the presence of 100 ,tg of EF for 24 h at 37°C. Duplicate control wells each containing 3 capillary tubes were set up for each treatment. Areas of macrophage migration were estimated at 24 h, and the percentage of migration inhibition with EF calculated. The significance of migration inhibition was assessed with Student's t test. A value of P<0 01 was considered indicative of significant migration inhibition. The effects Singer and his associates (1975) , using the MMI test, also demonstrated that 70% of women with carcinoma in situ and 42% of women with dysplasia showed a lymphocyte response to EF, and sensitization to EF has been demonstrated in other malignant diseases, using the same test Light et al., 1975) . The incidence of lymphocyte response to EF observed in the present study was lower than that reported by Singer and coworkers (1975) . This discrepancy may be due to differences in the classification system employed in the 2 studies; in the present study, women with mild and moderate dysplasia and those with severe dysplasia and carcinoma in situ were grouped together.
The observed incidence of lymphocyte response to EF in women with premalignant cervical lesions is considerably higher than for that in women with a variety of benign gynaecological conditions, and is about the same as that in women with invasive cervical carcinoma. A recent report by Flavell & Potter (1978) has shown that lymphocytes from 63% of cancer patients studied respond to EF in the MMI test, whilst lymphocytes from 32% of individuals with a variety of nonmalignant conditions showed a similar response. Thus, the incidence of lymphocyte response to EF seen in women with premalignant cervical lesions falls about halfway between those seen in cancer patients and patients with benign conditions. Caspary & Field (1971) , using the macrophage electrophoretic mobility (MEM) test, have demonstrated that lymphocytes from cancer patients not only respond to EF, but also to an acid extract of malignant tissues termed "cancer basic protein" (CaBP) . Further studies have shown that EF and CaBP have remarkable chemical similarities and it has been suggested that the EF and CaBP molecules share common antigenic determinants (Coates & Carnegie, 1975; McDermott et al., 1974; Flavell & Potter, 1978) . This has led to the proposal that the lymphocyte response to EF in malignant disease might represent a cellmediated immune response directed against neoantigens on the tumour-cell surface which share an antigenic determinant or determinants with EF. Thus, it is conceivable that the lymphocyte response to EF seen in women with premalignant lesions may be due to the appearance of a neoantigen or neoantigens on the dysplastic epithelial cell surface, which is immunologically cross-reactive with EF; indeed, the appearance of a lymphocyte response to EF in these women may prove to be an indicator of the malignant potential of these lesions.
Serum from most of the women with cervical dysplasia and carcinoma in situ who showed a lymphocyte response to EF abolished this response in vitro. Flavell & Potter (1978) have recently shown that serum from most cancer patients showing lymphocyte response to EF is capable of abolishing EF-mediated migration inhibition. Similarly, serum flow patients with non-malignant conditions who showed a lymphocyte response to EF, abolished this response in about half of these individuals. However, it is difficult to make a direct comparison between the incidence of serum abrogation of the lymphocyte response to EF seen in the present study and that seen by Flavell & Potter (1978) , in view of the small number of women with cervical dysplasia and carcinoma in situ investigated in the present study. However, this preliminary investigation suggests that women with premalignant cervical lesions might show a similar incidence of serum abrogation of the lymphocyte response to EF to that seen in cancer patients. have shown that a component(s) present in serum from cancer patients is capable of depressing the lymphocyte response to EF and CaBP in the MEM test. Further studies have shown that the C2 macroglobulin component of serum is responsible for this depression (Ford et al., 1973) . Furthermore, studies by Bernard & Lamoureux (1975) have shown that remixing (2 macroglobulin with EF abolishes the encephalitogenic and thus antigenic potency of the EF molecule. It is possible that the serum-blocking effects found in the present study may be due to the release of oU2-macroglobulin-like components to the circulation, which may perform some immunoregulatory function after tissue damage and subsequent release of normal tissue antigen. Thus, the production of serum factor(s) which abrogate EF sensitivity may have important implications in the immune response to premalignant and malignant lesions, and the detection of these factors may be of practical value in the laboratory diagnosis of such lesions.
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